United Asset Strategies Inc. Sells 1,385 Shares of Amgen Inc. $AMGN

United Asset Strategies Inc. trimmed its holdings in Amgen Inc. (NASDAQ:AMGN) by 4.2% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 31,269 shares of the medical research company’s stock after selling 1,385 shares during the period. United Asset Strategies Inc.’s holdings in Amgen were worth $13,180,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the business. BlackRock Inc. increased its position in Amgen by 4.8% in the 2nd quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock valued at $17,874,974,000 after acquiring an additional 2,261,544 shares during the period. State Street Corp raised its stake in Amgen by 38.2% during the 2nd quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock valued at $15,283,363,000 after acquiring an additional 11,656,755 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Amgen by 12.7% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,390,910 shares of the medical research company’s stock worth $1,952,156,000 after acquiring an additional 605,928 shares during the period. Bank of America Corp DE acquired a new stake in Amgen during the 2nd quarter worth approximately $1,831,903,000. Finally, Amundi lifted its position in Amgen by 15.2% during the 2nd quarter. Amundi now owns 3,890,189 shares of the medical research company’s stock worth $1,408,715,000 after acquiring an additional 512,883 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Analyst support: RBC Capital reaffirmed its Buy rating, while Goldman Sachs and TD Cowen also maintained Buy recommendations. The continued bullish view provides support ahead of earnings. RBC Capital Reaffirms Buy Rating
• Positive Sentiment: Rare-disease pipeline progress: Amgen reported Phase 3 data for dazodalibep in Sjögren’s disease, additional long-term UPLIZNA data in IgG4-related disease and other autoimmune conditions, and a diagnostic collaboration aimed at earlier rare-disease detection. The updates reinforce the company’s effort to expand growth beyond its established products. Rare Disease Updates
• Positive Sentiment: Dividend income: Amgen declared a quarterly dividend of $2.52 per share, or $10.08 annualized, payable December 11 to shareholders of record November 20. The dividend supports the stock’s income appeal. Amgen Fourth-Quarter Dividend
• Neutral Sentiment: Earnings catalyst: Amgen will report third-quarter 2026 results after the market close on November 3, followed by a conference call. Analysts are focused on whether strong sales of products such as Repatha and TEZSPIRE can offset rising expenses, pricing pressure and biosimilar competition. Amgen Third-Quarter Results Announcement
• Negative Sentiment: Profitability concerns: Management has warned that spending will increase, while MariTide trials could consume substantial cash. Investors are assessing whether higher research and development costs and a CFO transition could pressure margins. Amgen Expense and Profit Outlook

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on AMGN shares. Argus boosted their target price on Amgen from $375.00 to $460.00 and gave the company a “buy” rating in a report on Wednesday, August 19th. Sanford C. Bernstein increased their price target on Amgen from $335.00 to $345.00 and gave the stock a “market perform” rating in a report on Thursday, August 6th. UBS Group lifted their price objective on shares of Amgen from $430.00 to $470.00 and gave the company a “buy” rating in a research report on Friday, October 9th. Jefferies Financial Group reissued a “hold” rating and issued a $410.00 price objective on shares of Amgen in a research note on Wednesday, September 23rd. Finally, Mizuho boosted their price objective on shares of Amgen from $303.00 to $352.00 and gave the company a “neutral” rating in a research note on Tuesday, August 18th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, sixteen have issued a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $389.71.

Amgen Trading Up 2.0%

Shares of AMGN stock opened at $460.73 on Friday. The business’s fifty day moving average price is $419.32 and its 200 day moving average price is $374.09. The firm has a market capitalization of $249.08 billion, a PE ratio of 28.63, a P/E/G ratio of 3.31 and a beta of 0.41. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. Amgen Inc. has a 1-year low of $288.00 and a 1-year high of $468.27.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. The company had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%. Amgen’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same quarter last year, the company earned $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, sell-side analysts forecast that Amgen Inc. will post 22.96 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Friday, November 20th. Amgen’s dividend payout ratio (DPR) is currently 62.65%.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 2,970 shares of the business’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the sale, the senior vice president owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Rachna Khosla sold 2,000 shares of the company’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00. Following the transaction, the senior vice president owned 6,404 shares in the company, valued at $2,642,098.28. The trade was a 23.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 6,222 shares of company stock valued at $2,540,926 in the last quarter. Insiders own 0.85% of the company’s stock.

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.